.png)
"Nanorobot" is an emerging technology, belonging to “Molecular nanotechnology (MNT)” in robotics engineering.
Nanomedicine technology is a cross-integrated discipline, combining precision medicine with nanotechnology. The precision medicine plan provides a strong follow-up power for the accelerated commercialization of nanorobots. According to the China Business Industry Research Institute, the precision medicine market is expected to exceed 100 billion yuan in 2022; TrendForce Consulting estimates that the global market will reach 88.1 billion US dollars in 2025.
From the market distribution perspective, the major market for nanorobots is North America followed by Europe. Since the application of this technology requires a large amount of capital investment from medical institutions, as well as strengthening the training of employees, the Asia-Pacific region is expected to be the fastest-growing market for nanorobots.
At present, nanorobots for cancer treatment is still in the initial stage of research and development, and has not yet been realized in clinical practice. In the future, nanorobots for cancer treatment will inevitably have broad prospects for landing and room for development, with DNA nanorobots being the first to land.
The use of nanorobots in the medical industry has the following advantages:
Given the small nature of nano robots, they are able to move freely in the body and treat patients more easily
While surgery requires a scalpel which will leave scars, nanorobots do not require cutting through the tissue layers and thus, does less harm to the human body
Increased precision of operations by nano robots due to their ability to perform operations at the nano-scale
Nano robots are able to carry out directional treatment, which only diagnoses and treats the parts that have problems without causing damage to the other parts of the body
In addition to medical treatment, nanorobots have broad application prospects.
BCC research predicts that the global market for nanostructure applications in the life sciences will reach 17.8 billion U.S. dollars in 2019, and is expected to reach 33.8 billion U.S. dollars by 2024. The compound annual growth rate in the next five years is expected to be 13.7%. Sales (such as nanoparticles, nanospheres, nanocapsules and quantum dots) will continue to grow in the next five years. The global nanorobot market is expected to reach 100 billion U.S. dollars, with a compound annual growth rate of 21%. The breakthrough development of robotics is expected to create favorable demand for nano-robots.
Zooming in on China, the scale of China's nanotechnology market was approximately US$20 billion as of 2017. Although China's micro-nano market is in strong demand, the micro-nano industry is still in its infancy. Now there are about 300 research institutions nationwide, and about 300 companies of various types. However, local Chinese companies can only occupy a market of about US$5 billion. Therefore, China is a huge opportunity for nanorobot companies, and there is a high demand for nanorobots.
With Summer Atlantic Capital’s strategic partnership with Sinopharm, a leading healthcare group in China, we are able to strengthen the likelihood of a successful joint venture and support the medical technologies of foreign companies. Sinopharm will take a lead role in the CFDA approval process, sales & distribution, as well as potentially participating with direct investments into the joint venture itself either initially or as the JV expands. You can also contact us at info@summeratlantic.com if your company has any questions regarding our joint venture partnerships, distribution deals, or any other structures for Chinese expansion or for any general questions regarding the Chinese market.
Thank you and we look forward to working with you.
See LinkedIn Post: